AKT1 and colorectal carcinoma: Considering the small variations observed in the activation status of the PI3K/Akt and Wnt/β-catenin pathways in response to the treatments in HT-29 and HCT-116 cells, we expanded our evaluation to three more CRC cell lines (Caco-2, Lovo and SW480).